– SWITZERLAND, Basel – Roche Holding’s Board of Directors – at its December meeting – decided on first proposals for approval by the Annual General Meeting (AGM), scheduled for 1 March 2016. Professor Dr Beatrice Weder di Mauro, a member of the BoD since 2006, has decided to not stand for re-election at the AGM in 2016 following 10 years of tenure. The BoD proposes Dr Claudia Süssmuth Dyckerhoff, currently Senior Partner at McKinsey & Company and Sector leader Asia Health Services and Systems, for election to the BoD at the 2016 AGM.
Christoph Franz, Chairman of Roche said: “As a member of the Board and the Audit Committee, Beatrice Weder di Mauro has made significant contributions to Roche’s success with her broad expertise in economics. On behalf of the Roche Board of Directors, I would like to extend our sincerest thanks to her.” Christoph Franz added: “I am delighted with our nomination of Claudia Süssmuth Dyckerhoff for election as a new member of the Board. She is a leader with extensive international experience in strategic consultancy in the healthcare industry, especially in Asian growth markets.”
As announced in May 2015, Julie Brown will also be nominated for election at the AGM in 2016. She is replacing Dame DeAnne Julius, who has decided to not stand for re-election.
The following current members of the BoD are recommended for re-election:
|Name||Board member since|
|Dr Christoph Franz (as Chairman)||2011|
|Professor Dr Pius Baschera||2007|
|Professor Sir John Irving Bell||2001|
|Professor Dr Richard Lifton||2015|
|Dr Andreas Oeri||1996|
|Dr Severin Schwan||2013|
|Peter R. Voser||2011|
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014 the Roche Group employed over 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.